An Italian Experience on Grade 3b Follicular Lymphoma
An Italian Experience on Grade 3b Follicular Lymphoma
Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma.
Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.
Inclusion Criteria:
Exclusion Criteria:
bbotto@cittadellasalute.to.it+390116334553